COVID-19 Clinical Trials

Last Updated: Mar 19, 2021

Guidelines Used:

Downloadable: PDF and Word

In the last year, COVID-19 has spread worldwide rapidly, increasing incidence of infections and deaths. The Infectious Diseases Society of America (IDSA) and National Institute of Health (NIH) have spearheaded efforts to provide updated evidence-based guidelines to support treatment and management of patients with COVID-19 with researchers all over the world.

Based on a request, here is a summary of coronavirus-19 disease (COVID-19) guidelines and clinical trials **as of March 19, 2021**. Evidence is rapidly changing; please be diligent in viewing the latest evidence-based data.

COVID-19 Compiled Clinical Trials with their Therapies (as of March 19, 2021)

TherapyMOAAssociated Clinical Trials
HydroxychloroquineAntimalarialBarnabas et al, 8 December 2020Mitjà et al. 24 November 2020Self et al, 9 November 2020Rajasingham et al, 17 October 2020RECOVERY Collab group, 8 October 2020Abella et al, 30 September 2020Skipper et al, 16 July 2020RECOVERY, 5 June 2020Boulware et al, 3 June 2020
Hydroxychloroquine + azithromycinAntimalarial + macrolide antibioticCavalcanti et al, 23 July 2020
AzithromycinMacrolide antibioticPRINCIPLE, 21 March 2021Furtado et al, 4 September 2020
Lopinavir + ritonavirHIV type 1 aspartate protease inhibitor + boosterRECOVERY, 5 October 2020Horby et al, 29 June 2020
Hung et al, 8 May 2020Cao et al, 7 May 2020
CorticosteroidsAnti-inflammatory steroidRECOVERY Collab Group, 25 February 2021Tomazini et al, 2 September 2020Horby et al, 17 July 2020
TocilizumabMonoclonal antibody that inhibits interleukin (IL-6)Soin et al, 4 March 2021REMAP-CAP Investigators, 25 February 2021Veiga et al, 20 January 2021Salama et al. 17 December 2020Stone et al, 21 October 2020Hermine et al, 20 October 2020Salvarani et al, 20 October 2020
Tocilizumab + RemdesivirMonoclonal antibody + antiviralREMDACTA (Roche), 11 March 2021
Convalescent plasmaRecovered COVID-19 patient’s plasmaLibster et al, 18 February 2021REMAP-CAP trial 12 January 2021Simonovich et al, 24 November 2020Agarwal et al, 22 October 2020Li et al3 June 2020
RemdesivirBroad spectrum antiviralSolidarity (WHO), 2 December 2020Beigel et al, 8 October 2020Spinner et al, 21 August 2020Goldman et al, 27 May 2020Wang et al, 29 April 2020
FamotidineHistamine-2 receptor antagonistMulti-Site Adaptive Trials for COVID-19, ongoing
Bamlanivimab + etesevimabNeutralising IgG1 monoclonal antibody directed against SARS-CoV-2 spike proteinGottlieb et al, 21 January 2021
Bamlanivimab (LY-CoV555)*same as aboveBLAZE-2, 21 January 2021Chen et al, 21 January 2021ACTIV-3, 26 October 2020
Baricitinib + RemdesivirJanus-associated tyrosine kinase (JAK) 1 and 2 inhibitor (modulates immune response)Kalil et al, 11 December 2020
IvermectinAnti-parasiticLópez-Medina et al, 4 March 2021


Leave a Reply

Your email address will not be published. Required fields are marked *